MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis (original) (raw)

• Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610–621 (2006).
  Article CAS PubMed Google Scholar
• David, J. R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl Acad. Sci. USA 56, 72–77 (1966).
  Article CAS PubMed PubMed Central Google Scholar
• Sorg, C. Characterization of murine macrophage migration inhibitory activities (MIF) released by concanavalin A stimulated thymus or spleen cells. Mol. Immunol. 17, 565–569 (1980).
  Article CAS PubMed Google Scholar
• Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473–488 (2003).
  Article CAS Google Scholar
• Mikulowska, A., Metz, C. N., Bucala, R. & Holmdahl, R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J. Immunol. 158, 5514–5517 (1997). The first report of the participation of MIF in an animal model of RA.
  CAS PubMed Google Scholar
• Leech, M. et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum. 41, 910–917 (1998).
  Article CAS PubMed Google Scholar
• Leech, M., Metz, C., Bucala, R. & Morand, E. F. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum. 43, 827–833 (2000).
  Article CAS PubMed Google Scholar
• Santos, L. L., Hall, P., Metz, C. N., Bucala, R. & Morand, E. F. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin. Exp. Immunol. 123, 309–314 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Bernhagen, J. et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J. Exp. Med. 183, 277–282 (1996).
  Article CAS PubMed Google Scholar
• Onodera, S. et al. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1β. Arthritis Rheum. 50, 1437–1447 (2004).
  Article CAS PubMed Google Scholar
• Ichiyama, H. et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 26, 187–194 (2004).
  Article CAS PubMed Google Scholar
• Leech, M. et al. Regulation of p53 by macrophage migration inhibitory factor (MIF) in inflammatory arthritis. Arthritis Rheum. 48, 1881–1889 (2003). The first in vivo demonstration of the regulatory effect of MIF on p53 and apoptosis, which was confirmed in vitro in human RA cells.
  Article CAS PubMed Google Scholar
• Gregory, J. L. et al. Reduced leukocyte–endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum. 50, 3023–3034 (2004).
  Article CAS PubMed Google Scholar
• Leech, M. et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum. 42, 1601–1608 (1999).
  Article CAS PubMed Google Scholar
• Onodera, S. et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11, 163–167 (1999).
  Article CAS PubMed Google Scholar
• Morand, E. F. et al. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41, 558–562 (2002).
  Article CAS Google Scholar
• Sampey, A. V., Hall, P. H., Mitchell, R. A., Metz, C. N. & Morand, E. F. Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum. 44, 1273–1280 (2001).
  Article CAS PubMed Google Scholar
• Santos, L., Lacey, D. C., Yang, Y., Leech, M. & Morand, E. F. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor (MIF). J. Rheumatol. 31, 1038–1043 (2004).
  CAS PubMed Google Scholar
• Onodera, S. et al. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J. Biol. Chem. 275, 444–450 (2000).
  Article CAS PubMed Google Scholar
• Onodera, S. et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J. Biol. Chem. 277, 7865–7874 (2002).
  Article CAS PubMed Google Scholar
• Lacey, D. et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum. 48, 103–109 (2003).
  Article CAS PubMed Google Scholar
• Mitchell, R. A. et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl Acad. Sci. USA 99, 345–350 (2002).
  Article CAS PubMed Google Scholar
• Baugh, J. A. et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 3, 170–176 (2002).
  Article CAS PubMed Google Scholar
• Radstake, T. R. et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 52, 3020–3029 (2005).
  Article CAS PubMed Google Scholar
• Donn, R. et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum. 50, 1604–1610 (2004).
  Article PubMed Google Scholar
• Donn, R. P. et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J. Invest. Dermatol. 123, 484–487 (2004).
  Article CAS PubMed Google Scholar
• Amoli, M. M. et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J. Rheumatol. 29, 1671–1673 (2002).
  CAS PubMed Google Scholar
• Nohara, H. et al. Association of the −173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J. Gastroenterol. 39, 242–246 (2004).
  Article CAS PubMed Google Scholar
• Libby, P. Inflammation in atherosclerosis. Nature 420, 868–874 (2002).
  Article CAS PubMed Google Scholar
• Lusis, A. J. Atherosclerosis. Nature 407, 233–241 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Ross, R. The pathogenesis of atherosclerosis: perspective for the 1990s. Nature 362, 801–809 (1993).
  Article CAS PubMed Google Scholar
• Ross, R. Atherosclerosis — an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
  Article CAS PubMed Google Scholar
• Nissen, S. E. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29–38 (2005).
  Article CAS PubMed Google Scholar
• Hansson, G. K., Libby, P., Schonbeck, U. & Yan, Z. Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91, 281–291 (2002).
  Article CAS PubMed Google Scholar
• Schober, A. & Weber, C. Mechanisms of monocyte recruitment in vascular repair after injury. Antioxid. Redox Signal. 7, 1249–1257 (2005).
  Article CAS PubMed Google Scholar
• Burger-Kentischer, A. et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105, 1561–1566 (2002).
  Article CAS PubMed Google Scholar
• Burger-Kentischer, A. et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 184, 28–38 (2006).
  Article CAS PubMed Google Scholar
• Lin, S. G. et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ. Res. 87, 1202–1208 (2000).
  Article CAS PubMed Google Scholar
• Pan, J. H. et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109, 3149–3153 (2004).
  Article CAS PubMed Google Scholar
• Ip, J. H. et al. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J. Am. Coll. Cardiol. 15, 1667–1687 (1990).
  Article CAS PubMed Google Scholar
• Shah, P. K. Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation 107, 2175–2177 (2003).
  Article PubMed Google Scholar
• Chen, Z. et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 709–714 (2004).
  Article CAS PubMed Google Scholar
• Schober, A. et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109, 380–385 (2004).
  Article CAS PubMed Google Scholar
• Pan, J. H. et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J. Vasc. Surg. 37, 628–635 (2003).
  Article CAS PubMed Google Scholar
• Atsumi, T., Nishihira, J., Makita, Z. & Koike, T. Enhancement of oxidised low-density lipoprotein uptake by macrophages in response to macrophage migration inhibitory factor. Cytokine 12, 1553–1556 (2000).
  Article CAS PubMed Google Scholar
• Verschuren, L. et al. Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid. Redox Signal. 7, 1195–1202 (2005).
  Article CAS PubMed Google Scholar
• Kong, Y. Z. et al. Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 178, 207–215 (2005).
  Article CAS PubMed Google Scholar
• Kong, Y. Z. et al. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc. Res. 65, 272–282 (2005).
  Article CAS PubMed Google Scholar
• Kusuhara, M., Chait, A., Cader, A. & Berk, B. C. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol. 17, 141–148 (1997).
  Article CAS PubMed Google Scholar
• Hudson, J. D. et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375–1382 (1999). The first report of the unique inhibitory effect of MIF on p53 activity.
  Article CAS PubMed PubMed Central Google Scholar
• Mitchell, R. A. et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl Acad. Sci. USA 99, 345–350 (2002). Demonstration that the inhibitory effects of MIF on p53 are mediated via downregulation of p53 protein and involve cyclooxygenase 2.
  Article CAS PubMed Google Scholar
• Simelyte, E. et al. Regulation of arthritis by p53: critical role of adaptive immunity. Arthritis Rheum. 52, 1876–1884 (2005).
  Article CAS PubMed Google Scholar
• Mercer, J., Figg, N., Stoneman, V., Braganza, D. & Bennett, M. R. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ. Res. 96, 667–674 (2005). Describes the role of p53 in atherosclerosis in a model of atheroma.
  Article CAS PubMed Google Scholar
• Asanuma, Y. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407–2415 (2003).
  Article CAS PubMed Google Scholar
• Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399–2406 (2003).
  Article CAS PubMed Google Scholar
• Van Doornum, S., McColl, G. & Wicks, I. P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46, 862–873 (2002).
  Article CAS PubMed Google Scholar
• del Rincon, I. D., Williams, K., Stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737–2745 (2001).
  Article CAS PubMed Google Scholar
• Foote, A. et al. Macrophage migration inhibitory factor in systemic lupus erythematosus. J. Rheumatol. 31, 268–273 (2004).
  CAS PubMed Google Scholar
• Walsh, L. J., Wong, C. A., Pringle, M. & Tattersfield, A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Brit. Med. J. 313, 344–346 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005).
  Article CAS PubMed Google Scholar
• Yang, Y. et al. Modulation of inflammation and response to dexamethasone by annexin-1 in antigen-induced arthritis. Arthritis Rheum. 50, 976–984 (2004).
  Article CAS PubMed Google Scholar
• Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270, 286–290 (1995).
  Article CAS PubMed Google Scholar
• Ito, K. et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J. Exp. Med. 203, 7–13 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Choi, J. H. et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 2404–2409 (2005).
  Article CAS PubMed Google Scholar
• Wiley, R. E. et al. Transient corticosteroid treatment permanently amplifies the Th2 response in a murine model of asthma. J. Immunol. 172, 4995–5005 (2004).
  Article CAS PubMed Google Scholar
• Calandra, T. et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68–71 (1995). The first report of the unique relationship between MIF and glucocorticoids.
  Article CAS PubMed Google Scholar
• Roger, T., Chanson, A. L., Knaup-Reymond, M. & Calandra, T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur. J. Immunol. 35, 3405–3413 (2005). Describes the mechanism of MIF-mediated reversal of the anti-inflammatory effects of glucocorticoids, which involves MAP kinase phosphatase 1.
  Article CAS PubMed Google Scholar
• Aeberli, D. et al. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett. 580, 974–981 (2006). Reports that cells obtained from MIF-deficient mice have increased sensitivity to glucocorticoids.
  Article CAS PubMed Google Scholar
• Sapolsky, R. M., Romero, L. M. & Munck, A. U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21, 55–89 (2000).
  CAS PubMed Google Scholar
• Munck, A., Guyre, P. M. & Holbrook, N. J. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 5, 25–44 (1984).
  Article CAS PubMed Google Scholar
• Dhabhar, F. S. & McEwen, B. S. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc. Natl Acad. Sci. USA 96, 1059–1064 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Galon, J. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61–71 (2002).
  Article CAS PubMed Google Scholar
• Barnes, P. J. Anti-inflammatory actions of glucocorticoids — molecular mechanisms. Clin. Sci. 94, 557–572 (1998).
  Article CAS Google Scholar
• Faggiano, A. et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88, 2527–2533 (2003).
  Article CAS PubMed Google Scholar
• Colao, A. et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84, 2664–2672 (1999).
  CAS PubMed Google Scholar
• Pivonello, R., Faggiano, A., Lombardi, G. & Colao, A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol. Metab. Clin. North Am. 34, 327–339, viii (2005).
  Article CAS PubMed Google Scholar
• Kirilov, G. et al. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur. J. Endocrinol. 149, 549–553 (2003).
  Article CAS PubMed Google Scholar
• Hurwitz Eller, N., Netterstrom, B. & Hansen, A. M. Cortisol in urine and saliva: relations to the intima media thickness, IMT. Atherosclerosis 159, 175–185 (2001).
  Article CAS PubMed Google Scholar
• Maddali, K. K., Korzick, D. H., Turk, J. R. & Bowles, D. K. Isoform-specific modulation of coronary artery PKC by glucocorticoids. Vascul. Pharmacol. 42, 153–162 (2005).
  Article CAS PubMed Google Scholar
• Hermanowski-Vosatka, A. et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202, 517–527 (2005). Reports the role of glucocorticoids in accelerating atherosclerosis.
  Article CAS PubMed PubMed Central Google Scholar
• Feldmann, M. et al. Future prospects for anti-cytokine treatment. Ann. Rheum. Dis. 59 (Suppl. 1), 119–122 (2000).
  Article Google Scholar
• Taylor, P. C., Williams, R. O. & Feldmann, M. Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Curr. Opin. Biotechnol. 15, 557–563 (2004).
  Article CAS PubMed Google Scholar
• Thomson, A. W. The Cytokine Handbook (Academic, New York, 2003).
  Google Scholar
• Pugsley, M. K. Etanercept. Immunex. Curr. Opin. Investig. Drugs 2, 1725–1731 (2001).
  CAS PubMed Google Scholar
• Toussirot, E. & Wendling, D. The use of TNF-α blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother. 5, 581–594 (2004).
  Article CAS PubMed Google Scholar
• Braddock, M. & Quinn, A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nature Rev. Drug Discov. 3, 330–339 (2004).
  Article CAS Google Scholar
• Calandra, T. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Med. 6, 164–170 (2000).
  Article CAS PubMed Google Scholar
• Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756–759 (1993).
  Article CAS PubMed Google Scholar
• Sakai, Y. et al. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology 124, 725–736 (2003).
  Article CAS PubMed Google Scholar
• Leng, L. et al. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467–1476 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Meyer-Siegler, K. L., Leifheit, E. C. & Vera, P. L. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4, 34 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-α therapies: the next generation. Nature Rev. Drug Discov. 2, 736–746 (2003).
  Article CAS Google Scholar
• Thiele, M. & Bernhagen, J. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid. Redox Signal. 7, 1234–1248 (2005).
  Article CAS PubMed Google Scholar
• Kleemann, R. et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as a thiol-protein oxidoreductase. J. Mol. Biol. 280, 85–102 (1998).
  Article CAS PubMed Google Scholar
• Rosengren, E. et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2, 143–149 (1996). The first demonstration that human MIF has enzymatic activity.
  Article CAS PubMed PubMed Central Google Scholar
• Rosengren, E. et al. The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett. 417, 85–88 (1997).
  Article CAS PubMed Google Scholar
• Swope, M., Sun, H.-W., Blake, P. R. & Lolis, E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J. 1, 3534–3541 (1998).
  Article Google Scholar
• Bendrat, K. et al. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 36, 15356–15362 (1997).
  Article CAS PubMed Google Scholar
• Hermanowski-Vosatka, A. et al. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 38, 12841–12849 (1999).
  Article CAS PubMed Google Scholar
• Kleemann, R., Kapurniotu, A., Mischke, R., Held, J. & Bernhagen, J. Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81Ser MIF. Eur. J. Biochem. 261, 753–766 (1999).
  Article CAS PubMed Google Scholar
• Kleemann, R. et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408, 211–216 (2000).
  Article CAS PubMed Google Scholar
• Stamps, S. L., Fitzgerald, M. C. & Whitman, C. P. Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. Biochemistry 37, 10195–10202 (1998). Describes the structural characterization of the MIF catalytic pocket.
  Article CAS PubMed Google Scholar
• Lubetsky, J. B., Swope, M., Dealwis, C., Blake, P. & Lolis, E. Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry 38, 7346–7354 (1999).
  Article CAS PubMed Google Scholar
• Philo, J. S., Yang, T. H. & LaBarre, M. Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys. Chem. 108, 77–87 (2004).
  Article CAS PubMed Google Scholar
• Jasanoff, A., Wagner, G. & Wiley, D. C. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. EMBO J. 17, 6812–6818 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Taylor, A. B. et al. Crystal structure of macrophage migration inhibitory factor complexed with (E)-2-fluoro-_p_-hydroxycinnamate at 1.8 Å resolution: implications for enzymatic catalysis and inhibition. Biochemistry 38, 7444–7452 (1999).
  Article CAS PubMed Google Scholar
• Orita, M., Yamamoto, S., Katayama, N. & Fujita, S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr. Pharm. Des. 8, 1297–1317 (2002).
  Article CAS PubMed Google Scholar
• Morand, E. F., Leech, M. & Iskander, M. Therapeutic opportunities for antagonism of macrophage migration inhibitory factor. Expert Opin. Ther. Patents 8, 1189–1212 (2003).
  Article Google Scholar
• Dios, A. et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45, 2410–2416 (2002).
  Article CAS PubMed Google Scholar
• Lubetsky, J. B. et al. The tautomerase activity of MIF is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976–24982 (2002).
  Article CAS PubMed Google Scholar
• Senter, P. D. et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl Acad. Sci. USA 99, 144–149 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Zhuang, S. et al. Some insights into the stereochemistry of inhibition of macrophage migration inhibitory factor with 2-fluoro-_p_-hydroxycinnamate and its analogues from molecular dynamics simulations. J. Med. Chem. 48, 7208–7214 (2005).
  Article CAS PubMed Google Scholar
• Nguyen, M. T. et al. A sixteen residue peptide fragment of macrophage migration inhibitory factor, MIF(50–65), exhibits redox activity and has MIF-like biological functions. J. Biol. Chem. 278, 33654–33671 (2003).
  Article CAS PubMed Google Scholar
• Petrenko, O., Fingerle-Rowson, G., Peng, T., Mitchell, R. A. & Metz, C. N. MIF-deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J. Biol. Chem. 278, 11078–11085 (2003).
  Article CAS PubMed Google Scholar
• Petrenko, O. & Moll, U. M. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol. Cell 17, 225–236 (2005).
  Article CAS PubMed Google Scholar
• Nguyen, M. T. et al. The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J. Immunol. 170, 3337–3347 (2003).
  Article CAS PubMed Google Scholar
• Chamovitz, D. A. & Segal, D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep. 2, 96–101 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Wadgaonkar, R. et al. Intracellular interaction of myosin light chain kinase with macrophage migration inhibition factor (MIF) in endothelium. J. Cell. Biochem. 95, 849–858 (2005).
  Article CAS PubMed Google Scholar
• Swant, J. D., Rendon, B. E., Symons, M. & Mitchell, R. A. Rho GTPase-dependent signaling is required for MIF-mediated expression of cyclin D1. J. Biol. Chem. 280, 23066–23072 (2005).
  Article CAS PubMed Google Scholar
• Jung, H., Kim, T., Chae, H. Z., Kim, K. T. & Ha, H. Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J. Biol. Chem. 276, 15504–15510 (2001).
  Article CAS PubMed Google Scholar
• Lue, H. et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 18, 688–703 (2006).
  Article CAS PubMed Google Scholar
• Kleemann, R. et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408, 211–216 (2000).
  Article CAS PubMed Google Scholar
• Roger, T., David, J., Glauser, M. & Calandra, T. MIF regulates innate immune responses through modulation of Toll-like receptor-4. Nature 414, 920–924 (2001).
  Article CAS PubMed Google Scholar
• Al-Abed, Y. et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280, 36541–36544 (2005). The first in vivo demonstration of the beneficial effects of small-molecule MIF antagonists.
  Article CAS PubMed Google Scholar
• Cvetkovic, I. et al. Critical role of macrophage migration inhibitory factor (MIF) activity in experimental autoimmune diabetes. Endocrinology 146, 2942–2951 (2005).
  Article CAS PubMed Google Scholar
• Bacher, M. et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl Acad. Sci. USA 93, 7849–7854 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Calandra, T., Bernhagen, J., Mitchell, R. A. & Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179, 1895–1902 (1994).
  Article CAS PubMed Google Scholar
• Mitchell, R. A., Metz, C. N., Peng, T. & Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274, 18100–18106 (1999).
  Article CAS PubMed Google Scholar
• Chesney, J. et al. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5, 181–191 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Lacey, D. C. et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor (MIF). Arthritis Rheum. 48, 103–109 (2003).
  Article CAS PubMed Google Scholar